Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Top Cited Papers
- 11 September 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Molecular Psychiatry
- Vol. 13 (1), 27-35
- https://doi.org/10.1038/sj.mp.4002066
Abstract
Atypical antipsychotic drugs offer several notable benefits over typical antipsychotics, including greater improvement in negative symptoms, cognitive function, prevention of deterioration, and quality of life, and fewer extrapyramidal symptoms (EPS). However, concerns about EPS have been replaced by concerns about other side effects, such as weight gain, glucose dysregulation and dyslipidemia. These side effects are associated with potential long-term cardiovascular health risks, decreased medication adherence, and may eventually lead to clinical deterioration. Despite a greater understanding of the biochemical effects of these drugs in recent years, the pharmacological mechanisms underlying their various therapeutic properties and related side effects remain unclear. Besides dopamine D2 receptor antagonism, a characteristic feature of all atypical antipsychotic drugs, these agents also bind to a range of non-dopaminergic targets, including serotonin, glutamate, histamine, α-adrenergic and muscarinic receptors. This review examines the potential contribution of different receptors to metabolic side effects associated with atypical antipsychotic treatment for all seven agents currently marketed in the United States (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone and clozapine) and another agent (bifeprunox) in clinical development at the time of this publication.Keywords
This publication has 75 references indexed in Scilit:
- Antipsychotic drug-induced weight gain mediated by histamine H1receptor-linked activation of hypothalamic AMP-kinaseProceedings of the National Academy of Sciences, 2007
- Antipsychotic induced metabolic abnormalities: An interaction study with various PPAR modulators in miceLife Sciences, 2006
- Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind ContinuationNeuropsychopharmacology, 2006
- Clinical Drug Monitoring in Child and Adolescent Psychiatry: Side Effects of Atypical NeurolepticsJournal of Child and Adolescent Psychopharmacology, 2006
- Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapineInternational Journal of Neuropsychopharmacology, 2006
- Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: Sensitivity to study designAmerican Journal of Health-System Pharmacy, 2006
- Partial agonism and schizophreniaThe British Journal of Psychiatry, 2005
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001